Garda Therapeutics, a specialty assets company, has acquired Assertio and its chemotherapy supportive care treatment Rolvedon.
The deal is valued at $125.1 million.
Rolvedon is a treatment for chemo-induced infections.
Garda Therapeutics, a specialty assets company, has acquired Assertio and its chemotherapy supportive care treatment Rolvedon.
The deal is valued at $125.1 million.
Rolvedon is a treatment for chemo-induced infections.